Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers

Annals of Oncology

Volumn 24, Issue 7, 2013, Pages 1847-1852

  Brouckaert Dr , O ^a   Schoneveld, A ^a   Truyers, C ^b   Kellen, E ^a   Van Ongeval, C ^a   Vergote, I ^a   Moerman, P ^a   Floris, G ^a   Wildiers, H ^a   Christiaens, M R ^a   Van Limbergen, E ^a   Neven, P ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Independent statistician   (Belgium)

Author keywords

Breast cancer; Palpability; Prognosis; Screening; Subtypes

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER SCREENING; CANCER SPECIFIC SURVIVAL; DATA BASE; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PALPATION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR VOLUME;

BREAST CANCER; PALPABILITY; PROGNOSIS; SCREENING; SUBTYPES;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; EARLY DETECTION OF CANCER; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MAMMOGRAPHY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PALPATION; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR BURDEN;

EID: 84883802590     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt179     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Garne JP, Aspegren K, Balldin G et al. Increasing incidence of and declining mortality from breast carcinoma. Trends in Malmo, Sweden, 1961-1992. Cancer 1997; 79: 69-74.
3. Otten JD, Broeders MJ, Fracheboud J et al. Impressive time-related influence of the Dutch screening programme on breast cancer incidence and mortality, 1975-2006. Int J Cancer 2008; 123: 1929-1934.
4. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012; 380: 1778-1786.
5. Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004; 328: 921-924.
6. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009; 339: b2587.
7. Kalager M, Adami HO, Bretthauer M et al. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med 2012; 156: 491-499.
8. Dawson SJ, Duffy SW, Blows FM et al. Molecular characteristics of screendetected vs symptomatic breast cancers and their impact on survival. Br J Cancer 2009; 101: 1338-1344.
9. Chiarelli AM, Edwards SA, Sheppard AJ et al. on behalf of the Breast Screening Study Group. Favourable prognostic factors of subsequent screen-detected breast cancers among women aged 50-69. Eur J Cancer Prev 2012; 21: 499-506.
10. Gill G, Luke C, Roder D. Prognostic importance of palpability as a feature of screen-detected breast cancers. J Med Screen 2006; 13: 98-101.
11. Theriault RL, Litton JK, Mittendorf EA et al. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 2011; 11: 325-331.
12. Lai HW, Kuo SJ, Chen LS et al. Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller. Eur J Surg Oncol 2011; 37: 18-24.
13. Cancello G, Maisonneuve P, Rotmensz N et al. Prognosis in women with small (T1mic, T1a, T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat 2011; 127: 713-720.
14. Brouckaert O, Laenen A, Vanderhaegen J et al. Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol 2012; 23: 2578-2584.
15. EBCTCG. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087-2106.
16. Darby SC, Ewrtz M, McGale P et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368: 987-998.
17. Davies C, Pan H, Godwin J et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of estrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012; S0140-6736: 61963-1.
18. Narod SA, Valentini A, Nofech-Mozes S et al. Tumour characteristics among women with very low-risk breast cancer. Breast Cancer Res Treat 2012; 134: 1241-1246.
19. Güth U, Brenckle D, Huang DJ et al. Three-dimensional pathological size assessment in primary breast carcinoma. Breast Cancer Res Treat 2009; 116: 257-262. Epub 2008 Jul 12.
20. Chagpar AB, McMasters KM, Saul J et al. Body mass index influences palpability but not stage of breast cancer at diagnosis. Am Surg 2007; 73: 555-560. discussion 560.
21. Kwan ML, Chen WY, Kroenke CH et al. Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Res Treat 2012; 132: 729-739.
22. Niraula S, Ocana A, Ennis M et al. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat 2012; 134: 769-781.
23. Rakha EA, Ellis IO. Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. Adv Anat Pathol 2011; 18: 255-267.
24. Wo JY, Chen K, Neville BA et al. Effect of very small tumor size on cancerspecific mortality in node-positive breast cancer. J Clin Oncol 2011; 29: 2619-2627.